News about "chronic kidney disease "

AstraZeneca Pharma India Launches K+ Connect Initiative to Strengthen Hyperkalaemia Management in India

AstraZeneca Pharma India Launches K+ Connect Initiative to Strengthen Hyperkalaemia Management in India

AstraZeneca Pharma India has launched K+ Connect, a nationwide initiative bringing together multidisciplinary experts from 33 healthcare centres to strengthen long-term hyperkalaemia management in patients with heart failure and chronic kidney disease.

Chronic Kidney Disease | 14/05/2026 | By News Bureau

Alebund Pharmaceuticals Completes Enrollment in Global Phase 3 Trial for AP301 Hyperphosphatemia Therapy

Alebund Pharmaceuticals Completes Enrollment in Global Phase 3 Trial for AP301 Hyperphosphatemia Therapy

Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.

Chronic Kidney Disease | 07/05/2026 | By News Bureau 109

Mankind Pharma Urges Greater Kidney Health Awareness as CKD Burden Rises

Mankind Pharma Urges Greater Kidney Health Awareness as CKD Burden Rises

On World Kidney Day, Mankind Pharma highlights rising cases of Chronic Kidney Disease in India and stresses early screening, lifestyle changes and awareness to prevent late-stage diagnosis.

Chronic Kidney Disease | 12/03/2026 | By News Bureau 116

Insilico Medicine's AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Trial Under TaiGen Biotechnology Partnership

Insilico Medicine's AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Trial Under TaiGen Biotechnology Partnership

TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.

Chronic Kidney Disease | 09/03/2026 | By News Bureau 190

Amphastar Secures FDA Approval for Generic Iron Sucrose Injection

Amphastar Secures FDA Approval for Generic Iron Sucrose Injection

The US FDA has approved Amphastar's Abbreviated New Drug Application (ANDA) for iron sucrose injection, an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

Chronic Kidney Disease | 12/08/2025 | By Dineshwori 311


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members